The Department of Health and Human Services under Secretary Robert F. Kennedy Jr. has officially reversed the FDA’s previous restrictions on compounded peptide therapies, allowing substances including BPC-157 and Thymosin Alpha-1 to return to the U.S. market, according to Reuters Health. The policy shift marks a significant departure from the FDA’s 2022 guidance that had effectively removed these peptides from the compounding pharmacies’ formulary due to safety and efficacy concerns.
BPC-157, a synthetic peptide derived from a protein found in gastric juice, has been popular in regenerative medicine circles for purported tissue healing properties, while Thymosin Alpha-1 has been used to support immune function. Both substances had faced FDA scrutiny as the agency increased oversight of compounded drugs following reports of adverse events and questions about clinical evidence supporting their use.
The reversal comes amid broader changes at HHS under Kennedy’s leadership, which has emphasized expanding access to alternative and integrative medicine approaches. Industry observers note this decision aligns with Kennedy’s stated goals of reducing regulatory barriers for treatments popular in functional medicine and wellness communities. The move has been welcomed by compounding pharmacies and practitioners who argued the restrictions limited patient access to potentially beneficial therapies.
However, the policy change has drawn criticism from some medical experts who point to the limited clinical trial data supporting these peptides’ safety and efficacy. Critics argue that allowing these substances back on the market without requiring rigorous FDA approval sets a concerning precedent for drug regulation. Patient advocacy groups have expressed mixed reactions, with some celebrating increased treatment options while others worry about potential risks from inadequately studied compounds.
Healthcare providers can now resume prescribing these peptides through compounding pharmacies, though insurance coverage remains uncertain. Patients interested in these therapies should consult with qualified healthcare professionals and understand that compounded peptides are not FDA-approved drugs and lack the regulatory oversight of conventional pharmaceuticals.
